Product image of Levosimendan Accord (Levosimendan) supplied by GNH India

Levosimendan Accord

Active Ingredient:
Levosimendan
Origin:
EU

Levosimendan Accord (Levosimendan)

Levosimendan, the active ingredient in Levosimendan Accord, is a calcium sensitizer and potassium channel opener presented as an injectable solution for intravenous use. It is indicated for the treatment of acute decompensated heart failure in adult patients.

GNH India supplies Levosimendan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Accord Healthcare France Sas

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Levosimendan is used in the management of acute heart failure syndromes, where it improves cardiac performance and systemic circulation.
  • Acute decompensated heart failure: enhances cardiac output and relieves symptoms of congestion.
  • Post‑operative low cardiac output syndrome: supports myocardial contractility during recovery.
  • Severe systolic heart failure with low ejection fraction: provides inotropic support while reducing afterload.

How It Works

  • Levosimendan binds to troponin C in cardiac myocytes, increasing its sensitivity to calcium and thereby augmenting contractile force without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing cardiac preload and afterload, which together improve overall cardiac performance.

Side Effects

Levosimendan may be associated with several adverse reactions that clinicians monitor during therapy.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Hypotension: transient blood pressure reduction.
  • Nausea: occasional gastrointestinal upset.
  • Dizziness: related to blood pressure changes.
  • Flushing: warm sensation of skin.

Serious or Rare Side Effects

  • Severe hypotension: may require intervention.
  • Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
  • Myocardial ischemia: chest pain or ECG changes.
  • Anaphylactic reactions: rare allergic response.
  • Elevated liver enzymes: indicating hepatic stress.

Precautions & Warnings

  • When using Levosimendan, careful patient assessment and monitoring are essential.
  • Monitor blood pressure: watch for significant drops.
  • Observe cardiac rhythm: detect arrhythmias promptly.
  • Use cautiously in renal impairment: adjust therapy based on renal function.
  • Avoid in severe hypotension: contraindicated when systolic pressure is very low.
  • Check for hypersensitivity: discontinue if allergic signs appear.
  • Store at ambient temperature: keep in original packaging, protect from moisture and light.

Avoid Interactions

Levosimendan can interact with other cardiovascular agents; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

  • Concurrent vasodilators (e.g., nitroglycerin): may cause profound hypotension.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations.
  • Other calcium‑sensitizing inotropes: risk of excessive contractility.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may blunt inotropic effect.
  • ACE inhibitors or ARBs: additive blood pressure lowering.
  • Digoxin: potential for altered cardiac conduction.

Frequently Asked Questions

Levosimendan Accord is used to treat acute decompensated heart failure in adult patients. It improves cardiac contractility and reduces vascular resistance, helping to restore adequate blood flow and relieve symptoms such as shortness of breath and fluid overload.

Levosimendan sensitises troponin C to calcium, which enhances the strength of heart muscle contraction without increasing intracellular calcium. At the same time it opens ATP‑sensitive potassium channels in blood vessels, causing vasodilation and lowering the workload on the heart.

The dosing regimen for Levosimendan Accord is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. Healthcare professionals follow local guidelines and adjust the infusion rate as needed.

The safety of Levosimendan Accord in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Levosimendan Accord, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Unlike traditional inotropes that increase intracellular calcium, levosimendan enhances contractility by sensitising troponin C, which may reduce the risk of calcium‑mediated toxicity. Its additional vasodilatory effect via potassium‑channel opening can lower afterload, offering a dual mechanism that some clinicians prefer for certain acute heart‑failure scenarios.

Levosimendan Accord should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability.

Levosimendan Accord is given as an intravenous infusion. The preparation is added to a suitable diluent and administered through a controlled infusion pump under continuous monitoring of blood pressure, heart rate, and cardiac rhythm.

The most serious risks include severe hypotension, ventricular arrhythmias, and myocardial ischemia. Patients should be closely monitored for these events, and the infusion should be stopped immediately if any life‑threatening reaction occurs.

Levosimendan Accord is contraindicated in patients with known hypersensitivity to levosimendan or any of its excipients, and in those with severe hypotension (systolic blood pressure markedly below normal). Clinicians should also exercise caution in patients with significant renal or hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Levosimendan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT